DHAP regimen
|
WikiDoc Resources for DHAP regimen |
|
Articles |
|---|
|
Most recent articles on DHAP regimen Most cited articles on DHAP regimen |
|
Media |
|
Powerpoint slides on DHAP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on DHAP regimen at Clinical Trials.gov Clinical Trials on DHAP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on DHAP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on DHAP regimen Discussion groups on DHAP regimen Patient Handouts on DHAP regimen Directions to Hospitals Treating DHAP regimen Risk calculators and risk factors for DHAP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for DHAP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
DHAP regimen refers to a chemotherapy regimen consisting of dexamethasone, high-dose cytarabine (Ara-C) and cisplatin, used to treat relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.[1]
Regimen
DDexamethasone
HHigh Dose
ACytarabine (Ara-C)
PCisplatin
Indications
References
- ↑ 1.0 1.1 Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S; et al. (1988). "Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)". Blood. 71 (1): 117–22. PMID 3334893.